Company news

Dimerix Limited news in 2021

Dimerix Limited's news releases, calls and decks from 2021, newest first.

View company

Ethics Approval in Australia for Phase 3 COVID-19 Study

December 22, 2021

DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe

December 16, 2021

Pause in Trading

December 15, 2021

First Approvals Received for Start of Phase 3 FSGS Trial

October 20, 2021

Phase 3 DMX-200 COVID-19 Study Expands into Australia

October 14, 2021

Dimerix Closes SPP Oversubscribed

September 30, 2021

DMX-200 CLARITY COVID-19 Study Approval in India

September 24, 2021

Phase 3 Study in FSGS Kidney Patients Commences

August 24, 2021

SPP and Options Prospectus

August 23, 2021

Response to ASX Query

August 19, 2021

Successful $20m Placement to Fund Phase 3 Trials

August 15, 2021

DMX-200 COVID-19 Study Opens More Sites in Europe and UK

August 1, 2021

FDA Confirms Phase 3 Study Design in FSGS Kidney Disease

July 18, 2021

Dimerix Receives Innovation Passport and ILAP Designation

June 6, 2021

Dimerix Confirms Phase 3 FSGS Study Design With EMA

June 3, 2021

DMX-200 Remains Eligible for Accelerated Approval

May 27, 2021

COVID-19 Study Recruits Multiple Patients in Europe

April 22, 2021

Major Shareholder Loan for $5 Million

March 29, 2021

Clinical Study in Patients with COVID-19 Progresses

March 24, 2021

DMX-200 Competitive Position Further Enhanced

March 23, 2021

CLARITY 2.0 Study Progresses In Patients With COVID-19

March 9, 2021

Appendix 4D and Interim Financial Report

February 21, 2021

Dimerix Plans for Next Study in Diabetic Kidney Disease

January 27, 2021

Decks in 2021